Abstract:2030 Background: Approximately 5% of advanced stage breast cancer (BC) will develop leptomeningeal disease, a rare form of metastasis in the meninges, a membrane surrounding the brain and spinal cord. The prognosis for BC-LMD is dismal and currently available treatments are ineffective. For example, intrathecal (IT) therapy such as trastuzumab, and proton cranial spinal radiotherapy have only showed modest success. Dendritic cells are a master regulator of the immune system and play a critical role in bridging the innate and adaptive immune response. Here, we used a novel preclinical model to administer MHC class II peptide-pulsed conventional Type 1 dendritic cells (cDC1s) intrathecally in mice that harbor either HER2+ or triple negative breast cancer (TBNC) LMD. Our murine BC-LMD murine data lead us to open a Phase 1 clinical trial of cDC1s in HER2+ and TNBC LMD (NCT05809752; in progress). Methods: Our lab developed a “murine Ommaya” which mimics the clinically used Ommaya reservoir and allows for repeated intrathecal (IT) injections of novel drugs at 3 – 7µl volume directly into the CSF. We next developed a pipeline for screening immunogenic MHC class II peptides from tumor-associated oncodrivers and using these targets to generate tumor-targeting cDC1s. We tested the resulting vaccines in a preclinical model that IT delivers peptide-pulsed cDC1 cell therapy directly into the BC-LMD microenvironment. Results: We tested the efficacy of treatment in HER2+ LMD and TNBC-LMD models and found effective responses; LMD mice that received IT cDC1 therapy exhibited reduced tumor burden and prolonged survival that was significantly better than systemic therapy. Approximately 70% of mice from HER2+ LMD and 30% from TNBC LMD demonstrated complete responses. This was CD4+ T cell dependent. Notably, cured mice also showed signs of resistance against LMD recurrence upon rechallenge. Subsequent single cell RNA-seq (scRNA-seq) analyses of the CSF showed a shift in the innate immune landscape found in untreated LMD to an adaptive immune landscape. In addition, we noted the elevated secretion of Th1 proinflammatory cytokines such as IFN-γ in the CSF. This was recapitulated in the CSF samples of patients enrolled in an on-going phase 1 trial, where early data showed IT cDC1 triggered a high concentration of several proinflammatory cytokines. Conclusions: Our preclinical data suggest IT cDC1 vaccine is effective against BC-LMD and prevents LMD recurrence. We are currently investigating the mechanism(s) by which IT cDC1-initiates the CD4 Th1 adaptive immune response against LMD. By employing an scRNA-seq approach, we hope to further determine the roles of different immune cells and their subtypes in the CSF to IT cDC1s in mice and in patients. A future approach includes testing IT cDC1 platform in LMD from other cancers (e.g. melanoma etc.).

Recombinant adeno-associated virus encoding secondary lymphoid tissue chemokine(rAAV-SLC) efficiently infected mouse BMDC

More Than Chemotaxis: A New Anti-Tumor DC Vaccine Modified by Raav2-Slc

The anti-tumor effect and increased tregs infiltration mediated by rAAV-SLC vector

TO CONSTRUCT A RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR CARRYING THE GENE ENCODING THE MATURE PEPTIDE OF SECONDARY LYMPHOID-TISSUE CHEMOKINE

Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity.

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

Efficacy of Intrathecal Delivery of Peptide-Pulsed Type 1 Conventional Dendritic Cell Vaccine for the Treatment of Breast Cancer-Associated Leptomeningeal Disease in Preclinical Models.

Anti-nasopharyngeal carcinoma effect in vivo and in vitro of cytotoxicity T lymphocyte induced by Ad5-latent membrane protein 2A]

Antitumor Immunity by a Dendritic Cell Vaccine Encoding Secondary Lymphoid Chemokine and Tumor Lysate on Murine Prostate Cancer

Activation of Cytotoxic T Lymphocytes Against CML28-bearing Tumors by Dendritic Cells Transduced with a Recombinant Adeno-Associated Virus Encoding the CML28 Gene.

Co-transfection Gene Delivery of Dendritic Cells Induced Effective Lymph Node Targeting and Anti-tumor Vaccination

Dendritic cells infected with recombinant adenoviral vector encoding mouse fibroblast activation protein-α and human livin α exert an antitumor effect against Lewis lung carcinoma in mice

425 A Novel Dendritic Cell Vaccine Utilizing Mannan Anchored to Irradiated Tumor Cells in the Presence of Immune Adjuvants

Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of T-lymphocyte in human bladder tumor cell S in vitro

Soluble Expression of Recombinant Human Secondary Lymphoid Chemokine (SLC) in E. Coli and Research on Its in Vitro and in Vivo Bioactivity.

[Dendritic Cells Infected by Recombinant Adeno-Associated Virus with CEA Gene to Induce Antigen-Specific CTL Response to CD44(+)CD24(-/low) Cells from MCF-7 Breast Cancer Cell Line].

Rationally Designed Capsid and Transgene Cassette of AAV6 Vectors for Dendritic Cell‐based Cancer Immunotherapy

Enhanced Therapeutic Efficacy Of Tumor Rna-Pulsed Dendritic Cells After Genetic Modification With Lymphotactin

[Construction of Eukaryotic Expression Vector of Murine SLC Gene and Characterization of Its Chemotactic Function].

Induction of Specific Immune Response Against Hepatocellular Carcinoma by Human SLC and AFP Vector Transfected Dendritic Cells from CD34+ Hematopoietic Stem Cells

Anti-gastric carcinoma efficacy of gene modified dendritic cell vaccine recruited by macrophage inflammation protein-1